Published by Global Banking & Finance Review®
Posted on September 6, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on Google
Permira is selling Cambrex with a target valuation of $4 billion, according to the Financial Times. Reuters has not confirmed this report.
(Reuters) -British private equity firm Permira has put its contract drugmaker Cambrex up for sale, targeting a valuation of as much as $4 billion, the Financial Times reported on Saturday citing people familiar with the matter.
Reuters could not immediately verify the report.
(Reporting by Anusha Shah in Bengaluru; Editing by Aidan Lewis)
The British private equity firm Permira is selling its contract drugmaker Cambrex.
Permira is targeting a valuation of as much as $4 billion for Cambrex.
The Financial Times reported on the sale of Cambrex by Permira.
Explore more articles in the Finance category
